Business Standard

J&J expects Covid vaccine sales to jump as much as 46% in 2022

Delivery delays and an uneven demand during last year resulted in the drugmaker narrowly missing its goal of garnering $2.50 billion in vaccine sales in 2021.

Johnson & Johnson
Premium

Reuters
Johnson & Johnson said on Tuesday it expects to generate as much as $3.5 billion from the sale of its COVID-19 vaccine this year compared to $2.39 billion in 2021, in a sign of easing manufacturing problems and increasing demand.

Delivery delays and an uneven demand during last year resulted in the drugmaker narrowly missing its goal of garnering $2.50 billion in vaccine sales in 2021.

J&J shares fell 1.2% before the opening bell as overall fourth-quarter sales also missed market expectations due to a bleak performance by a few of the big revenue drivers such as cancer drug Imbruvica and Crohn's

Disclaimer: No Business Standard Journalist was involved in creation of this content

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Jan 25 2022 | 6:19 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com